Scinai Immunotherapeutics Ltd. (SCNI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Scinai Immunotherapeutics Ltd. (SCNI) trades at $0.294 with AI Score 56/100 (Grade B). Scinai Immunotherapeutics Ltd. is a development-stage biopharmaceutical company based in Israel, focusing on treatments for infectious and autoimmune diseases. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for SCNI: SCNI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SCNI against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
SCNI: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Scinai Immunotherapeutics Ltd. (SCNI) Healthcare & Pipeline Overview
Scinai Immunotherapeutics Ltd., an Israeli biopharmaceutical company, specializes in developing and commercializing nanosized antibody (NanoAb) therapies for infectious and autoimmune diseases. Through collaborations with Max Planck Society and University Medical Center Göttingen, Scinai aims to address unmet medical needs with innovative solutions in the biotechnology sector.
What Is the Investment Thesis for SCNI?
Scinai Immunotherapeutics presents a high-risk, high-reward investment profile typical of development-stage biopharmaceutical companies. The company's focus on NanoAb technology for infectious and autoimmune diseases offers potential for significant growth, contingent on successful clinical trials and regulatory approvals. Key value drivers include the advancement of its COVID-19 NanoAb program and the expansion of its pipeline into other disease indications through its collaboration with Max Planck Society and University Medical Center Göttingen. Investors should closely monitor clinical trial outcomes, regulatory milestones, and partnership developments. With a negative profit margin of -634.1% and a small market capitalization, Scinai's financial performance is highly dependent on future product commercialization and strategic partnerships.
Based on FMP financials and quantitative analysis
SCNI Key Highlights
Market Cap of $0.00B reflects its status as a development-stage company with limited current revenue.
- P/E Ratio of -0.14 indicates the company is currently unprofitable, typical for biotech firms investing heavily in R&D.
- Gross Margin of -114.4% highlights the high costs associated with research and development in the biotechnology sector.
- Beta of 1.90 suggests the stock is more volatile than the market, common for companies with binary outcomes (success or failure of drug development).
- No Dividend Yield reflects the company's focus on reinvesting earnings into research and development rather than returning capital to shareholders.
Who Are SCNI's Competitors?
SCNI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ENVB Enveric Biosciences, Inc. | $1.39 | +6.11% | — | |
| INDP Indaptus Therapeutics, Inc. | $1.38 | +46.81% | $156M | 47 |
| JSPR Jasper Therapeutics, Inc. | $0.69 | -7.42% | $11.2M | — |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.21% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SCNI's Key Strengths?
Innovative NanoAb technology platform.
- Strategic collaborations with leading research institutions.
- Focus on high-growth markets for infectious and autoimmune diseases.
- Experienced management team with expertise in biotechnology.
What Are SCNI's Weaknesses?
Development-stage company with limited revenue.
- High dependence on clinical trial outcomes and regulatory approvals.
- Small market capitalization and limited financial resources.
- Geographic concentration in Israel.
What Could Drive SCNI Stock Higher?
Clinical trial results for COVID-19 NanoAb program (expected Q4 2026).
- Announcement of new strategic partnerships (expected H2 2026).
- Regulatory submissions for NanoAb therapies (expected 2027).
- Expansion of NanoAb pipeline through collaborations.
- Advancements in personalized medicine applications.
What Are the Key Risks for SCNI?
Financial-distress signal — its Altman Z-Score of -11.29 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-29.8%) — the business is not currently generating profit on shareholder capital.
- Failure to achieve positive clinical trial results.
- Regulatory delays and hurdles in approvals.
- Competition from larger pharmaceutical and biotechnology companies.
- Dependence on strategic partnerships for funding and commercialization.
- Economic downturn and reduced healthcare spending.
What Are the Growth Opportunities for SCNI?
- Expansion of NanoAb Pipeline: Scinai's collaboration with Max Planck Society and University Medical Center Göttingen provides a platform for developing NanoAbs for a range of disease indications beyond COVID-19. The market for antibody therapeutics is projected to reach $300 billion by 2028, offering significant growth potential. Successful development and commercialization of new NanoAb therapies could drive substantial revenue growth for Scinai.
- Strategic Partnerships and Licensing Agreements: Scinai can leverage strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its NanoAb therapies. Licensing agreements can provide upfront payments, milestone payments, and royalties, generating revenue and validating the company's technology. The pharmaceutical industry is actively seeking innovative technologies, creating opportunities for Scinai to secure valuable partnerships.
- Geographic Expansion: While currently focused on Israel, Scinai has the potential to expand its market reach to other regions, particularly Europe and North America. Entering new markets would require regulatory approvals and strategic partnerships, but could significantly increase the company's revenue potential. The global market for infectious and autoimmune disease treatments is vast, offering ample opportunities for growth.
- Advancement of COVID-19 NanoAb Program: The ongoing COVID-19 pandemic and the emergence of new variants create a continued need for effective treatments. Scinai's COVID-19 NanoAb program has the potential to generate revenue through government contracts and commercial sales. Successful clinical trials and regulatory approval are critical milestones for this program.
- Personalized Medicine Applications: NanoAb technology can be adapted for personalized medicine applications, tailoring treatments to individual patients based on their specific genetic and immunological profiles. This approach has the potential to improve treatment efficacy and reduce side effects. The market for personalized medicine is growing rapidly, driven by advances in genomics and diagnostics. Scinai can capitalize on this trend by developing NanoAb therapies for personalized medicine applications.
What Are SCNI's Competitive Advantages?
- Proprietary NanoAb Technology: Scinai's expertise in NanoAb development provides a competitive advantage.
- Strategic Partnerships: Collaborations with leading research institutions enhance its innovation capabilities.
- Intellectual Property: Patents and other intellectual property protect its NanoAb therapies.
- First-Mover Advantage: Being an early mover in the NanoAb space provides a competitive edge.
What Does SCNI Do?
Scinai Immunotherapeutics Ltd., formerly known as BiondVax Pharmaceuticals Ltd., was founded in 2003 and is headquartered in Jerusalem, Israel. The company transitioned its focus to developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases after changing its name in September 2023. Scinai leverages its expertise in biotechnology to create innovative therapies, particularly through the use of nanosized antibodies (NanoAbs). Scinai's core strategy involves licensing and collaboration agreements to advance its product pipeline. A key partnership is with the Max Planck Society and University Medical Center Göttingen, focusing on the development and commercialization of a COVID-19 NanoAb, as well as NanoAbs for other disease indications. This collaboration underscores Scinai's commitment to addressing significant healthcare challenges with novel therapeutic approaches. As a development-stage company, Scinai is dedicated to advancing its research and development efforts to bring innovative solutions to market, primarily within Israel but with potential for broader international reach.
What Products and Services Does SCNI Offer?
- Develops nanosized antibody (NanoAb) therapies.
- Focuses on treatments for infectious and autoimmune diseases.
- Collaborates with Max Planck Society and University Medical Center Göttingen.
- Seeks to commercialize NanoAbs for various disease indications.
- Conducts research and development activities.
- Aims to prevent and treat illnesses in Israel and potentially beyond.
How Does SCNI Make Money?
- Develops proprietary NanoAb therapies through internal research and development.
- Partners with research institutions like Max Planck Society for technology and expertise.
- Out-licenses or co-develops therapies with larger pharmaceutical companies for commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties on product sales.
What Industry Does SCNI Operate In?
Scinai Immunotherapeutics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The market for infectious and autoimmune disease treatments is substantial and growing, driven by an aging population and increasing prevalence of chronic conditions. Scinai's focus on NanoAb technology positions it within a niche segment of the antibody therapeutics market. Competitors include larger pharmaceutical companies and specialized biotech firms. The company's success will depend on its ability to navigate the complex regulatory landscape, secure funding, and demonstrate clinical efficacy.
Who Are SCNI's Key Customers?
- Pharmaceutical companies seeking innovative therapies.
- Healthcare providers treating infectious and autoimmune diseases.
- Patients suffering from infectious and autoimmune diseases.
- Government agencies and public health organizations.
Scinai Immunotherapeutics Ltd. (SCNI) Valuation Context
Relative to its peer group, SCNI's quantitative score of 56/100 is below the peer average of 67/100.
SCNI Revenue & Earnings Trend
In Q1 2026, SCNI generated $488K in top-line revenue, marking a sequential increase of 85.0%. The company recorded net income of $3.6M, with diluted EPS of $3840.00. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, SCNI averaged $959.30 in diluted EPS.
Company Profile
Scinai Immunotherapeutics Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Jerusalem, IL. The company is led by CEO Amir Reichman. SCNI has traded publicly since 2015.
Key Financial Metrics
Return on equity for Scinai Immunotherapeutics Ltd. stands at -29.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.2%, showing how much profit it generates from its asset base. A current ratio of 1.35 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Scinai Immunotherapeutics Ltd.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -11.29 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Scinai Immunotherapeutics Ltd. has beaten Wall Street's EPS estimate in 5 of its last 6 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 43.4% above estimates on average.
SCNI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative NanoAb technology platform.
- Strategic collaborations with leading research institutions.
- Focus on high-growth markets for infectious and autoimmune diseases.
- Experienced management team with expertise in biotechnology.
Bear Case
- Development-stage company with limited revenue.
- High dependence on clinical trial outcomes and regulatory approvals.
- Small market capitalization and limited financial resources.
- Geographic concentration in Israel.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $487,674 | $4M | $3840.00 |
| Q4 2025 | $263,636 | -$2M | -$0.40 |
| Q3 2025 | $277,290 | -$2M | -$1.20 |
| Q2 2025 | $386,500 | -$2M | -$1.20 |
Based on FMP financials and quantitative analysis
SCNI Latest News
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Jul 28, 2026
-
12 Health Care Stocks Moving In Friday's After-Market Session
benzinga · Jul 24, 2026
-
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga · Jun 22, 2026
SCNI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SCNI.
Price Targets
Wall Street price target analysis for SCNI.
SCNI MoonshotScore
What does this score mean?
The MoonshotScore rates SCNI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Amir Reichman
CEO
Amir Reichman serves as the CEO of Scinai Immunotherapeutics Ltd. His background includes extensive experience in the biopharmaceutical industry, with a focus on strategic leadership and business development. He has a proven track record of driving innovation and growth in the healthcare sector. Reichman's expertise spans various aspects of the pharmaceutical value chain, from research and development to commercialization and market access.
Track Record: Since assuming the role of CEO, Amir Reichman has been instrumental in guiding Scinai Immunotherapeutics through a strategic transformation, focusing on the development of NanoAb therapies. He has overseen the establishment of key partnerships and collaborations, including the agreement with Max Planck Society and University Medical Center Göttingen. His leadership is focused on advancing the company's pipeline and creating long-term value for shareholders.
Scinai Immunotherapeutics Ltd. ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. For SCNI, as an ADR, it allows U.S. investors to easily invest in Scinai Immunotherapeutics without the complexities of cross-border transactions. The ADR is denominated in U.S. dollars, simplifying trading and reporting for U.S. investors.
- Home Market Ticker: Tel Aviv Stock Exchange, Israel
- ADR Level: 2
- ADR Ratio: 1:1
Scinai Immunotherapeutics Ltd. Healthcare Stock: Key Questions Answered
What does the AI Score mean for SCNI?
SCNI holds an AI Score of 56/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Scinai Immunotherapeutics Ltd. is a development-stage biopharmaceutical company based in Israel, focusing on treatments for infectious and autoimmune diseases. The company is leveraging nanosized …
What does Scinai Immunotherapeutics Ltd. do?
Scinai Immunotherapeutics Ltd. is a development-stage biopharmaceutical company focused on creating and commercializing innovative therapies using nanosized antibodies (NanoAbs). These NanoAbs are being developed for the prevention and treatment of infectious and autoimmune diseases. Through strategic collaborations, particularly with the Max Planck Society and University Medical Center Göttingen, Scinai is advancing its pipeline of NanoAb-based treatments, aiming to address unmet medical needs in Israel and potentially globally.
What do analysts say about SCNI stock?
As a development-stage company, Scinai Immunotherapeutics currently has limited analyst coverage. Valuation metrics are largely based on future potential rather than current financial performance. Key considerations include the successful advancement of its NanoAb pipeline, regulatory approvals, and strategic partnerships. Investors should conduct thorough due diligence and assess the inherent risks associated with investing in early-stage biotechnology companies.
What are the main risks for SCNI?
Scinai Immunotherapeutics faces several key risks inherent to the biotechnology industry. These include the risk of failure in clinical trials, which could significantly impact the company's valuation and future prospects. Regulatory hurdles and delays in obtaining approvals for its NanoAb therapies also pose a threat. Additionally, the company faces competition from larger pharmaceutical and biotechnology companies with greater resources.
What are the key factors to evaluate for SCNI?
Scinai Immunotherapeutics Ltd. (SCNI) holds an AI score of 56/100 (moderate). Scinai Immunotherapeutics presents a high-risk, high-reward investment profile typical of development-stage biopharmaceutical companies. Not financial advice.
How frequently does SCNI data refresh on this page?
SCNI's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SCNI's recent stock price performance?
Scinai Immunotherapeutics Ltd. (SCNI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative NanoAb technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SCNI overvalued or undervalued right now?
Scinai Immunotherapeutics Ltd. (SCNI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SCNI before investing?
Before investing in Scinai Immunotherapeutics Ltd. (SCNI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis pending for SCNI may provide additional insights.